Sign up to save your podcasts
Or
Share UroNurse Episode 106: New Immunotherapy Approaches for Bladder Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
UroNurse Episode 106: New Immunotherapy Approaches for Bladder Cancer
This activity is designed to provide the urology team with the latest developments and critical insights into bladder cancer management. This activity will also support the healthcare professional in their practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. To help ensure optimal patient care, this activity will provide clinicians with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with bladder cancer and the clinical utility of immunotherapy agents that could significantly impact patient outcomes.
Information on how to identify patients in their practices who would benefit from immunotherapy, and decide which neoadjuvant, adjuvant, or bladder-sparing strategies represent the optimal choice for each patient will be provided. In addition, identifying and treating adverse events that are likely to affect the majority of their patients being treated with immunotherapy will be discussed.
This activity is supported by educational grants from AstraZeneca and SeaGen.
*The information provided on the site is for educational purposes only, and does not substitute for professional medical advice. Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.
View all episodes
By UroNurse
5
66 ratings
This activity is designed to provide the urology team with the latest developments and critical insights into bladder cancer management. This activity will also support the healthcare professional in their practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. To help ensure optimal patient care, this activity will provide clinicians with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with bladder cancer and the clinical utility of immunotherapy agents that could significantly impact patient outcomes.
Information on how to identify patients in their practices who would benefit from immunotherapy, and decide which neoadjuvant, adjuvant, or bladder-sparing strategies represent the optimal choice for each patient will be provided. In addition, identifying and treating adverse events that are likely to affect the majority of their patients being treated with immunotherapy will be discussed.
This activity is supported by educational grants from AstraZeneca and SeaGen.
*The information provided on the site is for educational purposes only, and does not substitute for professional medical advice. Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.